Clinical Trial Update: Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria

View source ↗

Summary

A clinical trial update indicates the study on the role of the NLRP3 inflammasome in Escherichia coli and Staphylococcus aureus infections has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Escherichia Coli Infection
• Staphylococcus Aureus Infection

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Escherichia Coli Infections, Staphylococcus Aureus | Status: TERMINATED